AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie cash Dividends Declared ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Stockholders' Equity & Cash Flows
Latest, Q2 2026
3,074
Period ended Jun 30, 2026
Change on a year earlier
+5.5%
2,914 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cash Dividends Declared ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,074 | +5.5% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,074 | +5.5% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,075 | +5.5% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,917 | +5.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,914 | +5.8% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,913 | +5.8% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,914 | +5.8% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,757 | +4.7% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,754 | +4.8% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,753 | +4.7% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,755 | +4.3% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 2,634 | +4.9% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 2,628 | +4.7% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 2,630 | +4.6% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,642 | +5.0% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 2,512 | +8.3% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 2,511 | +8.3% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 2,514 | +8.5% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 2,517 | +8.7% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2021 | Sep 30, 2021 | 2,319 | +10.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 2,318 | +10.1% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 2,316 | +32.0% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 2,316 | +31.8% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 2,103 | +31.8% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 2,105 | +32.3% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,754 | +10.3% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,757 | +10.2% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,595 | +9.8% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,591 | +8.6% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,590 | +3.8% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,595 | – | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,453 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,465 | – | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,532 | – | Form 10-Q (filed 2019-05-03) ↗ |
Breakdown
What makes up cash dividends declared ($m)
- Dividends Declared per Common Share ($/sh)1.73 · Q2 2026
- Cash Paid for Purchases of Common Stock ($M)9 · Q2 2026
- Common Stock Held in Treasury (M shares)77.10 · Q2 2026
- Treasury Stock Carrying Value ($M)10,618 · Q2 2026
- Stock-Based Compensation Expense ($M)166 · Q2 2026
- Stock-Based Compensation Tax Benefit ($M)29 · Q2 2026
Cite this data
StockData. (2026). AbbVie Cash Dividends Declared ($M) ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cap_div_decl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.